The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

Phase 1 Unknown 24 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety of co-administration of DWP16001 2 mg and DWC202010 (DWC202010 37.5 mg) in healthy adults compared to the case of administration alone.

Timeline

Start: 2021-12-10
Primary completion: 2022-08
Completion: 2022-08

Publications

Yoon S, Park MS, Jin BH, Shin H, Na J, Huh W, Kim CO. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects. Expert Opin Drug Metab Toxicol. 2023 Jul-Dec;19(7):479-485. doi: 10.1080/17425255.2023.2249397. Epub 2023 Aug 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DWP202010	Unknown	37.5 mg	Oral
Subject	Enavogliflozin	Small molecule	2 mg	Oral

Indications

No indication recorded.